Long-term Effects of Thymosin Alpha 1 Treatment
Conditions
Keywords
long-term, thymosin alpha 1, sepsis, immunotherapy
Brief summary
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy. Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
Interventions
DRUGThymosin Alpha1
Drug interventions have been done in previous clinical studies
Sponsors
Sun Yat-sen University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Sepsis patients in the TESTS study Patients who discharged from hospital after recovery
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| three years mortality | 3 years | Mortality rate of patients treated with thymosin α1 or placebo within 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence rate of sepsis | 5 years | Percentage of recurrent sepsis within 5 years of discharge sepsis patients |
| one year mortality | 1 year | Mortality rate of patients treated with thymosin α1 or placebo within 1 year |
| Five years mortality | 5 years | Mortality rate of patients treated with thymosin α1 or placebo within 5 years |
| short form 36 questionnaire | 1 year | Quality of life of sepsis patients after 1 year of thymosin α1 or placebo treatment |
Contacts
Primary ContactJianfeng Wu
Backup ContactFei Pei
Outcome results
None listed